Varda Space is launching a commercial mission to manufacture pharmaceutical compounds in microgravity, marking one of the first deals to develop medicine molecules in orbit and return them to Earth.
The partnership between Varda Space and United Therapeutics represents an early-stage effort to leverage the unique conditions of low Earth orbit for drug development. Microgravity environments enable the creation of drug molecules with properties difficult or impossible to achieve on the ground, potentially improving therapeutic effectiveness.
Varda CEO Will Bruey has signaled confidence in the commercial viability of orbital pharmaceutical manufacturing, suggesting additional missions may follow. The company plans to send medicines into space and retrieve them for further analysis and development.
While still in early phases, the deal signals growing interest from pharmaceutical companies in space-based research. Several firms have explored microgravity applications for protein crystals and drug formulations. Success could open a new market segment for commercial space ventures seeking revenue beyond satellite deployment and tourism.
The missions will test whether orbital manufacturing can deliver measurable advantages in drug efficacy, manufacturing efficiency, or cost—key factors determining whether space-based pharma production becomes economically viable at scale.
Thyme Care, a virtual platform addressing gaps in cancer treatment, secured $125 million in Series E funding, reaching a valuation exceeding $2 billion.
Wonderful has secured $550 million in Series C funding, more than doubling its valuation in under six months. The company plans to accelerate product development and expand its full-stack development engineering (FDE) teams.
Austin-based HiddenLayer raised $100 million in Series B funding led by Delta-v Capital. The security startup protects AI models, agents, and workflows from threats.
Artificial intelligence coding startup Cognition AI is closing a funding round that would value the company at approximately $47 billion. The raise marks a major milestone for the rapidly expanding AI sector.